KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Liabilities and Shareholders Equity (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Liabilities and Shareholders Equity for 17 consecutive years, with $7.6 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 8.66% year-over-year to $7.6 billion, compared with a TTM value of $22.2 billion through Dec 2025, down 20.1%, and an annual FY2025 reading of $7.6 billion, up 8.66% over the prior year.
  • Liabilities and Shareholders Equity was $7.6 billion for Q4 2025 at Biomarin Pharmaceutical, up from $7.5 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $7.6 billion in Q4 2025 and bottomed at $5.9 billion in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $6.6 billion, with a median of $6.6 billion recorded in 2023.
  • Peak annual rise in Liabilities and Shareholders Equity hit 11.25% in 2021, while the deepest fall reached 2.93% in 2021.
  • Year by year, Liabilities and Shareholders Equity stood at $6.0 billion in 2021, then rose by 6.17% to $6.4 billion in 2022, then increased by 7.32% to $6.8 billion in 2023, then rose by 2.15% to $7.0 billion in 2024, then increased by 8.66% to $7.6 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for BMRN at $7.6 billion in Q4 2025, $7.5 billion in Q2 2025, and $7.1 billion in Q1 2025.